Status:
TERMINATED
Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Lead Sponsor:
University of Washington
Collaborating Sponsors:
CLL Global Research Foundation
Conditions:
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
This study evaluates the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL...
Detailed Description
OUTLINE: For patients who have not been vaccinated at the time of enrollment, they will undergo collection of blood samples prior to the first vaccine dose, just before the second vaccine dose, and t...
Eligibility Criteria
Inclusion
- Age \>= 18 years
- A diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
- Willing and able to participate in all required evaluations and procedures in this study
Exclusion
- Any evidence of prior SARS-CoV-2/COVID19 infection
Key Trial Info
Start Date :
March 18 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2024
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT04852822
Start Date
March 18 2021
End Date
July 1 2024
Last Update
August 2 2024
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
City of Hope
Duarte, California, United States, 91010
2
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, United States, 92868
3
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, United States, 20007
4
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, United States, 33136